Lin Zhijun, Chen Yanchao, Long Jiangying, Zhang Xianhua
Department of Nephrology, The Second Affiliated Hospital, Shantou University Medical College Shantou 515041, Guangdong, China.
Clinical Laboratory, The Second Affiliated Hospital, Shantou University Medical College Shantou 515041, Guangdong, China.
Am J Transl Res. 2025 Feb 15;17(2):1057-1064. doi: 10.62347/HWYM7712. eCollection 2025.
To investigate the correlation between serum levels of decoy receptor 3 (DcR3), neutrophil-to-lymphocyte ratio (NLR), and Fas with the prognosis of liver cirrhosis, with the aim of providing clinical reference for the evaluation of cirrhosis.
123 patients with liver cirrhosis were retrospectively selected as the observation group, and 123 healthy individuals as the control group. Serum DcR3, Fas, and peripheral blood NLR were measured and compared between groups. Differences in these indicators were analyzed among patients with varying cirrhosis types and those with liver cancer. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive value of each indicator for cirrhosis progression to liver cancer.
Serum levels of DcR3, Fas, and peripheral blood NLR were significantly higher in the observation group compared to the control group (P < 0.05). Among cirrhosis subtypes, patients with liver cancer exhibited the highest levels of DcR3, Fas, and NLR, followed by those with decompensated cirrhosis, with the lowest levels observed in patients with compensated cirrhosis (P < 0.05). Additionally, cirrhosis patients showed significantly higher levels of these markers than compensated cirrhosis patients (P < 0.05). Among patients with different grades of cirrhosis, the levels of each indicator were highest in grade C, followed by grade B, and lowest in grade A (P < 0.05). ROC curve analysis showed that DcR3, Fas, and NLR were significant predictors of cirrhosis progression to liver cancer (P < 0.05).
Serum levels of DcR3, Fas, and peripheral blood NLR increase with the progression of liver cirrhosis, demonstrating significant diagnostic value for assessing the prognosis of cirrhosis.
探讨血清诱骗受体3(DcR3)、中性粒细胞与淋巴细胞比值(NLR)及Fas水平与肝硬化预后的相关性,旨在为肝硬化评估提供临床参考。
回顾性选取123例肝硬化患者作为观察组,123例健康个体作为对照组。检测并比较两组血清DcR3、Fas及外周血NLR。分析不同肝硬化类型及合并肝癌患者这些指标的差异。采用受试者工作特征(ROC)曲线分析评估各指标对肝硬化进展为肝癌的预测价值。
观察组血清DcR3、Fas水平及外周血NLR均显著高于对照组(P<0.05)。在肝硬化亚型中,合并肝癌患者的DcR3、Fas及NLR水平最高,其次为失代偿期肝硬化患者,代偿期肝硬化患者水平最低(P<0.05)。此外,肝硬化患者这些标志物水平显著高于代偿期肝硬化患者(P<0.05)。在不同分级的肝硬化患者中,各指标水平C级最高,其次为B级,A级最低(P<0.05)。ROC曲线分析显示,DcR3、Fas及NLR是肝硬化进展为肝癌的显著预测指标(P<0.05)。
血清DcR3、Fas水平及外周血NLR随肝硬化进展而升高,对评估肝硬化预后具有重要诊断价值。